PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Category: Business
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
INCHEON, Korea–(BUSINESS WIRE)– #BYOOVIZ–Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimi…
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced achievement of statis…
Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today issued the following statement reg…
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
GENEVA & LAKE FOREST, Calif.–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today …
NextGen Healthcare and Eyefinity Align to Expand Offerings for Optometrists and Ophthalmologists
RANCHO CORDOVA, Calif.–(BUSINESS WIRE)– #NextGenHealthcare–NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, today announced the enhancement of its offerings for optometrists and ophthalmologists thro…
National Vision Holdings, Inc. Announces Third Quarter 2025 Earnings Release and Conference Call
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025, and will host a conference call…
IntelePeer Introduces SmartAnalytics Starter Pack to Accelerate AI Adoption and Measurably Improve Business and Patient Outcomes
DANIA BEACH, Fla.–(BUSINESS WIRE)–IntelePeer, the trusted leader in AI-powered automation and analytics for customer and patient interactions, today introduced at HLTH 2025 the SmartAnalytics™ Starter Pack. The Pack gives multi-site healthcare organi…
Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today iss…
Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration, a Leading Cause of Blindness, The New England Journal of Medicine Reports
ALAMEDA, Calif.–(BUSINESS WIRE)–The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial demonstrating the efficacy of Science Corporation’s PRIMA brain-computer interface…
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #AAO2025–Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase …
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 an…
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
BOSTON–(BUSINESS WIRE)–Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
Het programma van Dompé voor NAION geselecteerd voor het baanbrekende FDA Commissioner’s National Priority Voucher programma
MILAAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, een toonaangevend biofarmaceutisch bedrijf met activiteiten in Italië en de VS, heeft vandaag bekendgemaakt dat het door de Amerikaanse Food and Drug Administration (FDA) is geselecteerd om deel te ne…
Le programme de Dompé dans le domaine de la NAION sélectionné pour le programme national prioritaire du commissaire de la FDA
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, a annoncé aujourd’hui avoir été sélectionnée par la Food and Drug Administration (FDA) américaine pour participer au…
Seleccionan el programa de Dompé en NAION para el emblemático programa Acerca del programa piloto de Vales de Prioridad Nacional del Comisionado de la FDA
MILAN Y SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, una biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado hoy que ha sido seleccionada por la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) para participar…
Dompés Programm zu NAION wird für richtungsweisendes FDA-Programm Commissioner’s National Priority Voucher ausgewählt
MAILAND & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, ein führendes biopharmazeutisches Unternehmen mit Niederlassungen in Italien und den USA, gab heute bekannt, dass es von der US-amerikanischen Food and Drug Administration (FDA) für die Teilnahme am …
Il programma di Dompé sulla NOIA-NA selezionato per il prestigioso programma Commissioner’s National Priority Voucher della FDA
MILANO & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato di essere stata selezionata dalla Food and Drug Administration (FDA) statunitense per partecipare…
Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®)
FAR HILLS, N.J.–(BUSINESS WIRE)– #AMD–Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®)
IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansi…